Sunitinib-induced severe toxicities in a Japanese patient with the ABCG2 421 AA genotype

Sunitinib is a multi-targeted receptor tyrosine kinase inhibitor that acts against receptors of vascular endothelial growth factor (VEGF) and platelet-derived growth factor [1]. Sunitinib therapy has dramatically improved the clinical outcome of patients with advanced renal cell carcinoma (RCC) [2]. Common toxicities with sunitinib treatment include hypertension, hand–foot syndrome, vomiting, and diarrhea, and the proportion of grade 3 or 4 adverse events associated with sunitinib range from 1 to 13% for all categories [2]. A pharmacokinetics/pharmacodynamics meta-analysis in patients with advanced solid tumors, including patients with gastrointestinal stromal tumor (GIST) and metastatic RCC, indicated that increased exposure to sunitinib was associated with improved clinical outcomes in parallel with a degree of increased risk of adverse effects [3]. Previous studies suggested that several single-nucleotide polymorphisms (SNPs), including those in genes that are relevant to the pharmacokinetics of sunitinib such as CYP3A5 (cytochrome P450, family 3, subfamily A, polypeptide 5) and ABCG2 (ATP-binding cassette, sub-family G (WHITE), member 2), might be associated with its toxicities [4, 5].

In June 2011, a previously healthy 73-year-old female was found to have multiple lung nodules via a chest X-ray performed as part of a routine health checkup. A computer tomography (CT) scan revealed a 6-cm-sized left kidney mass and multiple lung nodules. She had no past medical history, such as hypertension, cardiovascular disease, or hyperlipidemia; with the exception that she had received orally-dosed alendronate at 35 mg a week for the prevention of osteoporosis. The patient was referred to our hospital and underwent a left-side nephrectomy. Histopathologically, the left kidney mass was diagnosed as a clear cell RCC with sarcomatoid components, a Fuhrman nuclear grade of 4, and pT3a. Four weeks after the nephrectomy, sunitinib therapy was initiated at a standard regimen of 50 mg once daily for 4 weeks, followed by 2 weeks without treatment. Physical examination of the patient before starting treatment revealed no abnormalities: her blood pressure was 128/76 mmHg, SpO₂ was 97% in room air, and performance status was 0. Blood examination showed normal complete blood counts, creatinine, transaminases, and bilirubin. On day 3 of sunitinib administration, the patient’s blood pressure increased to 180/90 mmHg. Treatment with amlodipine (5 mg, once daily) was commenced, and the sunitinib treatment was temporarily discontinued. On day 4, the patient’s hypertension had improved and sunitinib treatment was resumed at same dose. On day 11, the patient suffered from a fever of 38.4°C; the sunitinib treatment was discontinued on day 12. On day 14, she was admitted to hospital because the fever had persisted and she developed fatigue, anorexia, dyspnea and hypoxia (SpO₂ 93% room air), all of which were of grade 2 according to the Common Terminology Criteria for Adverse Events (CTCAE), version 4.03. A chest X-ray did not reveal any signs of pleural effusion or heart congestion. The laboratory value showed thrombocytopenia (platelet count, 56 × 10⁹/L) and liver dysfunction (aspartate aminotransferase [AST], 205 IU/L; alanine aminotransferase [ALT], 151 IU/L). We ruled out infectious disease and made a presumed diagnosis of sunitinib-related toxicities, because no evidence of infection was detected in blood, urine, and sputum cultures. On day 15 and 16, platelet transfusions were performed. On day 18, the patient’s dyspnea and hypoxia were exacerbated to grade 3 (SpO₂ was 88% room air at rest, and continuous supplemental oxygen was required at rest). A chest X-ray and CT scan revealed bilateral pleural effusion and pulmonary edema (Figure 1). An echocardiography showed no signs of cardiac dysfunction. Supportive care using supplemental oxygen and diuretics were undertaken. On day 25, all toxicities including fever, dyspnea, hypoxia, liver dysfunction, and thrombocytopenia had resolved (Figure 2, upper).The patient underwent an objective response evaluation based on a CT scan on day 25. The tumor size had decreased to 30% based on the Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1, despite the administration of sunitinib for just 10 days (Figure 3).

For subsequent elucidation and evaluation of the case, the plasma concentrations of sunitinib and its major metabolite N-desethyl sunitinib (SU12662), which has equal activity to sunitinib, from the plasma samples stored at −20°C on days 14, 16, 18, 20, 22, and 25 were determined by high performance liquid chromatography (HPLC)-UV. HPLC-UV was equipped with a chromatographic system consisted of a model L-7100 pump, D-7000 interface, L-7400 UV-visible detector, L-7200 autosampler and L-7300 column oven (Hitachi, Japan). Chromatographic separations were obtained under gradient conditions using a CAPCELL PAK C18 MG analytical column (250 × 2.0 mm, 5 μm particle size; Shiseido, Japan). Standard curves were prepared in the concentration range of 5 to 4mL/mL for sunitinib and 5 to 2mL/mL for SU12662 [6]. The plasma concentrations of sunitinib and SU12662 on day 14 were 131.9 ng/mL and 28.4 ng/mL, respectively (Figure 2, lower).

Genotyping of seven SNPs in CYP3A5 (6986A > G), ABCB1 (ATP-binding cassette, sub-family B (MDR/TAP), member 1; 1236C > T, 2677G > T/A, and 3435C > T), and ABCG2 (34G > A, 376G > A, and 421C > A) that are potentially relevant to the pharmacokinetics of sunitinib [7‐11] was performed using a genomic DNA sample extracted from formalin-fixed paraffin-embedded normal renal tissue blocks with a QIAamp DNA FFPE Tissue Kit (QIAGEN, Germany), because blood was not available for DNA extraction owing to this being a posthumous investigation. The institutional ethics committees of Toranomon Hospital and RIKEN approved this study. Written informed consent was obtained from the patient’s representatives. PCR amplification was first carried out in a 20-μl reaction mixture containing 10 ng of genomic DNA, 10 × Vogelstein buffer, 20 mM dNTPs, 2.5 U of TAKARA Ex Taq (Takara Bio, Otsu, Japan) and 10 pmol of each forward and reverse primer (Additional file 1: Table S1) under the following conditions using a GeneAmp PCR System 9700 (Applied Biosystems, Foster City, CA, USA): initial denaturation at 95°C for 5 min, 40 cycles at 95°C for 15 sec, 60°C for 30 sec and 72°C for 90 sec, and a final extension at 72°C for 5 min. Direct sequencing of the PCR products was then performed using the BigDye Terminator v.3.1 Cycle Sequencing Kit according to the manufacturer’s protocol on an ABI 3730xl DNA Analyzer (Applied Biosystems). The SNPs of CYP3A5, ABCB1, and ABCG2, which potentially affect sunitinib metabolism and transport, were genotyped. The genotypes of four SNPs in CYP3A5 and ABCB1 were heterozygous for the variant alleles in this patient. The genotypes of ABCG2 34G > A, 376G > A, and 421C > A were homozygous for the wild-type, wild-type, and variant alleles, respectively (Table 1).

We here report a patient with metastatic RCC who developed severe sunitinib-induced toxicities, including hypertension, high fever, liver dysfunction, and thrombocytopenia, after only 10 days administration of sunitinib. Despite immediate discontinuation of sunitinib, these symptoms persisted for over a week, and subsequent life-threatening hypoxia due to pleural effusion and pulmonary edema occurred. A phase I dose-escalation study of sunitinib administered daily on a 4-weeks-on, 2-weeks-off schedule indicated that most patients with a dose-limiting toxicity (DLT), including thrombocytopenia, hypertension and asthenia, had a combined (sunitinib plus SU012662) trough plasma concentration of ≥1mL/mL [12]. The combined plasma concentration of sunitinib and SU12662 on day 14 in this case was 160.3 ng/mL, even when measured at 3 days after the discontinuation of sunitinib.

Several factors can be attributed to the pathogenesis of the significantly high plasma concentrations of sunitinib and SU12662. First, co-administration of sunitinib with strong inhibitors of CYP3A4 and/or intake of grapefruit increase sunitinib concentration; however, our patient did not take these in parallel with sunitinib treatment. Second, we assumed that the patient might be a carrier of the variant alleles of SNPs in CYP3A5, ABCB1, and/or ABCG2 that cause higher plasma concentrations of sunitinib. ABCG2, the so-called breast cancer resistance protein (BCRP), is an ATP-binding cassette (ABC) drug transporter that facilitates the efflux of various tyrosine kinase inhibitors, including sunitinib, from cells. The ABCG2 421C > A polymorphism is associated with reduced ABCG2 protein expression and/or activity [13]. The reduced protein levels of the AA genotype in ABCG2 421C > A in the apical membranes of small intestinal enterocytes, hepatocytes, and renal proximal tubule epithelial cells might affect intestinal absorption and/or elimination after oral administration of sunitinib, leading to extremely high systemic exposure to sunitinib. Kim et al. reported that the ABCG2 421 AA genotype is mostly associated with the risk of sunitinib-related toxicities, such as thrombocytopenia, neutropenia and hand–foot syndrome, in Korean patients with metastatic RCC; however, the pharmacokinetics data was not shown [5]. Mizuno et al. reported a Japanese case with the ABCG2 421 AA genotype that developed severe toxicities due to high exposure of sunitinib and SU12662 [14]. Additionally, they demonstrated the ABCG2 421A > C genotype as a significant covariate associated with lower oral clearance by generating a population pharmacokinetics model of sunitinib from 19 Japanese patients with RCC, in which the number of patients with ABCG2 421 CC, CA and AA genotypes were 10, 8, and 1, respectively. The plasma concentration–time profiles simulated with repeated sunitinib doses of 50 mg/day based on the model showed that trough concentrations after 14 days for most ABCG2 421C > A carriers exceed 100–130 ng/mL [15]. However, the plasma concentration of sunitinib in our patient on day 14, when the administration of sunitinib has been discontinued for three days after repeated doses of 50 mg/day, was 131.9 ng/mL.

The elimination half-life of sunitinib calculated from its plasma concentrations on days 14, 16, 18, 20, and 22 in our patient was 50.1 hours, similar to that previously reported (41–86 hours) [12]. Therefore, it could be explained that the high exposure of sunitinib was caused by the loss of ABCG2 protein expression by genetic polymorphism. In the present study, the genotypes of SNPs in CYP3A5 and ABCB1, which are potentially related to the pharmacokinetics of sunitinib [7‐11], were heterozygous for the variant alleles, indicating that these SNPs might also be involved in the high systemic exposure of sunitinib to the patient.

Another population pharmacokinetics study also identified ethnic background as a significant covariate for the prediction of oral clearance [16]. The frequency of the ABCG2 421 AA genotype is higher in Asian populations (Japanese, 7% [13]; Korean, 8% [17]; and Chinese, 12% [18]) than in non-Asian populations (Caucasian, 1.7% and African, 0.2% [18]). Thus, this racial difference in the frequency of the ABCG2 421 AA genotype could explain the higher frequency of grade 3 and 4 sunitinib-related toxicities in Asians than in non-Asians [19, 20].

Our report suggests that pharmacogenetic factors should be considered when severe and rapid-onset adverse drug reactions develop in Asians treated with sunitinib.